ASSESSMENT OF HEADACHE IN MEN TAKING PHOSPHODIESTERASE-5 INHIBITOR (TADALAFIL) FOR ERECTILE DYSFUNCTION
[ N/A ]
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Carbone Editore
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aims: Tadalafil, a selective inhibitor of the cyclic guanosine monophosphate (cGMP) degrading phosphodiesterase 5 (PDE5), is known to cause headache as a secondary effect. This study was undertaken to assess the frequency, clinical characteristics of headache prospectively in a group of erectile dysfunction patients taking tadalafil as a PDE inhibitor. Materials and methods: As the first step of study, the question about having ever headache in last year was asked. Of the 31 patients, 16 patients (51.6%) had yes as an answer for the presence of headache. A questionnaire was given to the patients who had experienced headache whether recurrent or not. When patients were at headache-free period, tadalafil (20 mg) was administrated to each patient. The question about having headache was asked 5 hours and 48 hours later. According to the answer of this question, second questionnaire was conducted. The analysis of questionnaires was made separately. International Classification of Headache Disorders (ICHD) has been used for the case definition criteria. Results: A statistical significant difference was observed for the occurrence of headache between the baseline, 5th and 48th hours (p=0.001, cochrans Q test). However, we found no significant difference in headache occurrence between fifth hour and 48th hour of tadalafil 20 mg administration (p=0.687, Mc Nemar test). Conclusion: So from this study, it can be concluded that tadalafil can trigger headache attacks within the half-life of the drug.
Açıklama
Anahtar Kelimeler
Erectile dysfunction, Headache, Phosphodiesterase
Kaynak
Acta Medica Mediterranea
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
30
Sayı
5
